Searched for
GALVUS
Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...- Stocks in news: Bank of Baroda, SBI, Vedanta, JSW Steel, CiplaPublic sector lender Bank of Baroda recorded healthy advances growth for the March quarter, showing a growth of nearly 19% over the previou...
- Don’t foresee any disruptions due to Covid-19: Vasant Narasimhan, CEO, NovartisNovartis is one of the oldest pharma MNCs known for anti-cancer and anti-diabetic drugs. Despite the patent expiry for its popular anti-dia...
- USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...
- Domestic pharma retail market grows 13% in JulyAnti-diabetic therapy dominated the pecking order with four of the top 10 brands, Galvus MET and Janumet being the other top grossers.
- Novartis India ex-chief Jawed Zia joins rival AbbottAbbott in the second largest drug maker in India but it competes with Novartis in several therapy areas like cardiovascular, and diabetes. ...
- Former Novartis India Head Jawed Zia may Join AbbottNovartis India, with domestic sales of nearly Rs 1,200 crore, has been battling it out in the Indian market with several drug companies in ...
- 4 pharma companies under CCI scanner over price-fixingNovartis, Abbott among cos served notice for alleged cartelisation in diabetic drug.
- CCI starts probe on alleged price fixing of key anti diabetic drugsEmcure also did not respond to an email query as of press time while USV remained unreachable for a comment.
- Anti-diabetic drug cartel issue reaches CCI, Health MinistryCCI had been informed about the cartelisation allegations in a letter dated Feb 27, ET reported earlier. At that time, Novartis had denied ...
- NPPA to look into diabetes drug price-fixing allegationsVildagliptin is a proprietary drug of Novartis sold under the brand Galvus and comes under a new class of anti-diabetic drugs known as DPP ...
- Five diabetes drugs in top-10 selling list; overtakes anti-infective, antibiotic medsInsulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-sell...
- NeoBiocon partners Novartis to launch diabetes drugs in UAENeoBiocon has received approvals from the Ministry of Health-UAE for marketing Jalra and Jalra-M in the country and the launch is scheduled...
- Novartis India vice-chairman & managing director, Ranjit Shahani says company now focuses on new products, business growthNovartis India has over the past year launched three successful patented drugs and over 12 generic drugs that have helped it expand its pre...
- MNC drug companies like Roche, Merck Serono, Novartis see top deck reshuffleThese companies not only had to battle slow growth but also the fickle stand of Indian government over issues of intellectual property and ...
- Novartis sales team involved in bribing stockists for over a yearStockists had complained that Novartis' sales representatives had been offering massive discounts in order to push sales.
- Novartis sacks 18 for fabricating sales dataThe Indian subsidiary of Swiss drug maker Novartis has dismissed some 18 middle-level sales executives for fabricating and inflating the sa...
- Pharma MNCs eye Indian companies to collaborate on drugs, moleculesTo take advantage of the robust growth of the domestic pharma industry, MNCs are looking at alliances and partnerships.
- Novartis ties up with USV to market Galvus in IndiaNovartis has tied up with leading healthcare company - USV - to market its anti-diabetic product Galvus.
- New drug could halt progress of type 2 diabetesDiabetes patients starting out on GlaxoSmithKline’s drug Avandia have a better chance of keeping blood sugar levels within safe limits than...
Load More
